Eptinezumab-jjmr
Eptinezumab-jjmr
Eptinezumab-jjmr (pronounced as ep-ti-nez-u-mab jjmr) is a monoclonal antibody designed for the prevention of migraine.
Etymology
The name Eptinezumab-jjmr is derived from the International Nonproprietary Names (INN), where 'Epti' is the prefix for targeting CGRP receptor, 'mab' is the suffix for monoclonal antibodies, and 'jjmr' is the substem for human origin.
Usage
Eptinezumab-jjmr is used for the preventive treatment of migraine in adults. It is administered by intravenous infusion.
Mechanism of Action
Eptinezumab-jjmr works by binding to the calcitonin gene-related peptide (CGRP) ligand and blocking its binding to the receptor. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraines.
Side Effects
Common side effects of Eptinezumab-jjmr include upper respiratory tract infection, fatigue, and nausea.
Related Terms
External links
- Medical encyclopedia article on Eptinezumab-jjmr
- Wikipedia's article - Eptinezumab-jjmr
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski